The Neuropathology Core is an essential part of the Alzheimer's Disease Core Center (ADCC). During life, the signs and symptoms of Alzheimer's disease (AD) are not sufficiently different from several other conditions, resulting in misdiagnosis, even at the most advanced centers, in about 25% of subjects. Examination of the brain after death by a certified Neuropathologist is therefore the only means by which a definite diagnosis can be attained, allowing all research results to be correctly interpreted. A second major role of the Neuropathology Core is to provide neuropathologically characterized brain tissue to basic scientists, both within the ADCC and outside it, enabling them to discover the underlying molecular mechanisms of disease and design appropriate therapeutic interventions. A detailed understanding of the genetic and molecular processes of disease pathogenesis, obtained by comparative study of diseased and non-diseased brain tissue, remains the major approach to finding such interventions. A third important goal of the Neuropathology Core is to help develop a collaborative synergy that will enhance the research productivity of the entire Center.
Our Specific Aims are as follows: 1)To provide precise neuropathoiogic diagnoses of patients that have been clinically studied by the Cinical Core. 2) To provide basic scientists with neuropathologically characterized brain tissue suitable for the elucidation of the molecular mechanisms of AD and related disorders, and especially to assist researchers in their studies of the earliest stages of Alzheimer's disease, with the goal of identifying therapeutic strategies that will prevent the disease or slow its progress. 3) To share neuropathological skills, expertise, knowledge and data with all ADCC investigators and the scientific community at large, facilitating a collaborative synergy that will enhance the research productivity of all.

Public Health Relevance

The Arizona Alzheimer's Disease Center's Neuropathology Core provides autopsy services, brain measurements and diagnoses, and brain and body samples from research participants in the Clinical Core who have died and donated their brains (and sometimes their bodies) to advance the scientific understanding, treatment and prevention of Alzheimer's disease. It works closely with the other Cores and plays a critical role in the scientific fight against Alzheimer's Disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-13
Application #
8501205
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$235,669
Indirect Cost
$96,029
Name
Banner Sun Health Research Institute
Department
Type
DUNS #
960181055
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Ortuño-Lizarán, Isabel; Esquiva, Gema; Beach, Thomas G et al. (2018) Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson's disease. Acta Neuropathol Commun 6:90
Chakrabarty, Paramita; Li, Andrew; Ladd, Thomas B et al. (2018) TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. J Exp Med 215:2247-2264
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Andrews, Megan; Tousi, Babak; Sabbagh, Marwan N (2018) 5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress. Neurol Ther 7:51-58
Grilli, Matthew D; Wank, Aubrey A; Bercel, John J et al. (2018) Evidence for Reduced Autobiographical Memory Episodic Specificity in Cognitively Normal Middle-Aged and Older Individuals at Increased Risk for Alzheimer's Disease Dementia. J Int Neuropsychol Soc 24:1073-1083
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826

Showing the most recent 10 out of 794 publications